No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease

BRAIN

OXFORD UNIV PRESS

1. Regional Health Authority of Western Norway [911903, 911988]
2. Research Council of Norway [240369/F20]
3. Michael J. Fox Foundation
4. AbbVie
5. Avid Radiopharmaceuticals
6. Biogen Idec
7. BioLegend
8. Bristol-Meyers Squibb
9. GE Healthcare
10. Genentech
11. GlaxoSmithKline
12. Eli Lilly and Company
13. Lundbeck
14. Merck
15. Meso Scale Discovery
16. Pfizer Inc.
17. Piramal Imaging
18. Roche CNS group
19. Sanofi Genzyme
20. Servier
21. Takeda
22. Teva
23. UCB
24. Golub Capital